ArticleJournal of orthopaedic surgery and research2025
BMSC-derived exosomal lncRNA-ZFAS1 regulates the proliferation and differentiation of osteoblasts via the miR-9/IGF-1 signaling axis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone marrow mesenchymal stem cell exosomes in osteonecrosis: pathological mechanisms and therapeutic strategies.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoblast formation and function are essential for regulating bone disorders such as osteoporosis. Recent studies have confirmed that long non-coding RNAs (lncRNAs) from exosomes (ExOs) are involved in osteoblast proliferation and differentiation. This study investigated the role of bone marrow mesenchymal stem cell (BMSC)-derived exosomal lncRNA-ZFAS1 in regulating osteoblasts.
methodsHuman BMSCs and derived exosomes (BMSC-EXOs) were isolated and characterized. ZFAS1, miR-9, and IGF-1 levels in BMSC-EXOs and osteoblasts were measured by RT-qPCR and Western blot. ZFAS1 localization was determined by fluorescence in situ hybridization (FISH) and nuclear-cytoplasmic fractionation. ZFAS1 interactions with miR-9 and IGF-1 were confirmed via dual-luciferase reporter assay and RNA-binding protein immunoprecipitation (RIP). The effects of the ZFAS1/miR-9 axis on osteoblast proliferation and differentiation were examined using CCK-8, Alizarin Red staining, and ALP staining assays.
resultsBMSC-EXOs exhibited elevated ZFAS1 levels and efficiently delivered this lncRNA to osteoblasts. Through this mechanism, ZFAS1 enhanced osteoblast proliferation and differentiation. Mechanistically, ZFAS1 inhibited miR-9 expression, and downregulation of miR-9 reversed the suppression of osteoblast proliferation and differentiation induced by ZFAS1 silencing. The decrease in miR-9 leads to an increase in IGF-1, thereby promoting the proliferation and differentiation of osteoblasts.
conclusionsWe have shown that ZFAS1 from BMSC-derived EXOs enhances the proliferation and differentiation of osteoblasts by regulating the miR-9/IGF-1 signaling axis. This discovery provides novel insights into mechanisms of osteoblast proliferation and differentiation, and identifies potential therapeutic targets for treating associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.